INC Research intends to offer biopharmaceutical customers an integrated suite of tools to increase decision-making speed, efficiency and flexibility.
In addition, the collaboration would help in risk management, investment control and maximizing ROI in clinical development.
INC Research customers are believed to benefit from SAS software which will help achieve more rapid and informed decisions, faster time to market, and improved cash flow.
INC Research CEO James Ogle said the customers are seeking innovative solutions and enhanced efficiencies in drug development.
"By joining forces with SAS and its advanced analytics platform, INC Research can help customers better predict commercially successful outcomes earlier in the process to maximize development efforts," Ogle added.